Enliven Therapeutics, Inc. (ELVN) NASDAQ

22.12

+0.71(+3.32%)

Updated at October 20 04:00PM

Currency In USD

Enliven Therapeutics, Inc.

Address

6200 Lookout Road

Boulder, CO 80301

United States of America

Phone

720 647 8519

Sector

Healthcare

Industry

Biotechnology

Employees

62

First IPO Date

March 12, 2020

Key Executives

NameTitlePayYear Born
Mr. Samuel S. Kintz M.B.A.Co-Founder, Chief Executive Officer, Secretary & Director973,8001986
Mr. Benjamin HohlChief Financial Officer & Head of Corporate Development488,5001989
Dr. Joseph P. Lyssikatos Ph.D.Co-Founder & Chief Scientific Officer709,4001965
Dr. Helen Louise Collins M.D.Chief Medical Officer746,4001963
Mr. Anish Patel Pharm.D.Co-Founder & Chief Operating Officer01980
Dr. Galya D. Blachman Esq., Ph.D.Chief Legal Officer & Head of Business Development01977

Description

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.